[5] Moon HS, et al
Pacheco et al., 2022)
Who GLP-1 weight loss is for - and who it isn't Patients we typically work with on GLP-1 weight management: Adults with BMI 30+ (obesity) who have not achieved sustained weight loss with lifestyle change alone Adults with BMI 27+ and weight-related comorbidities - type 2 diabetes, hypertension, dyslipidemia, sleep apnea, prediabetes, fatty liver disease Patients with insulin resistance or metabolic syndrome where the metabolic and weight pictures are intertwined Patients post-bariatric surgery with weight regain, where appropriate and coordinated with their surgical team GLP-1 medications are not appropriate for patients with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, severe gastroparesis, or active eating disorders
Oral semaglutide Oral semaglutide, marketed as Rybelsus, was the first oral GLP-1 receptor agonist
In summary, GLP-1R on -cells is activated and promotes growth inhibitory hormone secretion, creating a multilayered inhibitory mechanism that effectively reduces glucagon secretion, and in turn lowers blood glucose levels
This litigation centers on serious claims against pharmaceutical giants Novo Nordisk and Eli Lilly and Co., alleging that they failed to adequately warn users about potential severe digestive side effects associated with these GLP-1 class drugs, which are commonly prescribed for diabetes management and weight loss
